Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START-lung: Tarlatamab in Pretreated ES-SCLC and ECOG PS 2
NCT07203053Phase 2Recruiting
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Apr 2026
- Primary completion
- Oct 2029
- Countries
- 5
01
Overview
A Phase 2 trial of tarlatamab in small cell lung cancer (SCLC), sponsored by ETOP IBCSG Partners Foundation. Started Apr 2026; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07203053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07203053.